

Systemic Lupus Erythematosus: Diagnosis and Treatment

Nguyet-Cam V. Lam, MD; Judy Abu Brown, MD; and Richa Sharma, MD

St. Luke's Bethlehem Family Medicine Residency, St. Luke's University Hospital, Bethlehem, Pennsylvania

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects the cardiovascular, gastrointestinal, hematologic, integumentary, musculoskeletal, neuropsychiatric, pulmonary, renal, and reproductive systems. It is a chronic disease and may cause recurrent flare-ups without adequate treatment. The newest clinical criteria proposed by the European League Against Rheumatism/American College of Rheumatology in 2019 include an obligatory entry criterion of a positive antinuclear antibody titer of 1:80 or greater. Management of SLE is directed at complete remission or low disease activity, minimizing the use of glucocorticoids, preventing flare-ups, and improving quality of life. Hydroxychloroquine is recommended for all patients with SLE to prevent flare-ups, organ damage, and thrombosis and increase long-term survival. Pregnant patients with SLE have an increased risk of spontaneous abortions, stillbirths, preeclampsia, and fetal growth restriction. Preconception counseling regarding risks, planning the timing of pregnancy, and a multidisciplinary approach play a major role in the management of SLE in patients contemplating pregnancy. All patients with SLE should receive ongoing education, counseling, and support. Those with mild SLE can be monitored by a primary care physician in conjunction with rheumatology. Patients with increased disease activity, complications, or adverse effects from treatment should be managed by a rheumatologist. (*Am Fam Physician.* 2023;107(4):383-395. Copyright © 2023 American Academy of Family Physicians.)

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. Its course is typically recurrent, with periods of relative remission followed by flare-ups. SLE can affect anyone, but it is more common in women between 15 and 44 years of age. The incidence and prevalence of SLE in North America are 23.2 per 100,000 person-years and 241 per 100,000 people, respectively.¹

Classification Criteria

Clinicians should have high suspicion for SLE in patients with symptoms involving multiple organ systems. Three classification approaches have evolved and provide some perspective on features of the disease, but these are not diagnostic criteria. These classification criteria are designed to standardize patients for entry into clinical trials. However, these criteria are often used clinically to evaluate patients.

Based on the 1997 update of the 1982 American College of Rheumatology (ACR) criteria, patients meet criteria for

SLE if they have four or more of the 11 symptoms.^{2,3} However, it was noted that not all patients meeting the criteria will have lupus and not all patients with clinically diagnosed lupus will meet the threshold criteria of four or more of the 11 symptoms.^{4,5} Because of this, the Systemic Lupus International Collaborating Clinics (SLICC) proposed new criteria in 2012.⁶ According to the SLICC criteria, patients must meet at least four criteria, including at least one clinical and one immunologic criterion, or the patient should have a biopsy confirming lupus nephritis and elevated

WHAT'S NEW ON THIS TOPIC

Systemic Lupus Erythematosus

The newest clinical criteria proposed by the European League Against Rheumatism/American College of Rheumatology in 2019 include an obligatory entry criterion: a positive antinuclear antibody titer of 1:80 or greater.

Patients with chronic kidney disease should receive one dose of pneumococcal conjugate vaccine (PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of pneumococcal polysaccharide vaccine (PPSV23).

Anifrolumab (Saphnelo) and voclosporin (Lupkynis) are new medications approved by the U.S. Food and Drug Administration in 2021 for the management of systemic lupus erythematosus.

CME This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 348.

Author disclosure: No relevant financial relationships.

Patient information: A handout on this topic is available with the online version of this article.

SYSTEMIC LUPUS ERYTHEMATOSUS

antinuclear antibody (ANA) or anti-double-stranded DNA (anti-dsDNA) levels without any other criteria.⁶ The SLICC criteria have increased sensitivity (97%) and decreased specificity (84%) compared with the ACR criteria.⁶

The newest clinical criteria proposed by the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) in 2019 include an obligatory entry criterion of a positive ANA titer of 1:80 or greater.

TABLE 1

Criteria for Classifying Systemic Lupus Erythematosus

System	ACR criteria (1997)*	SLICC criteria (2012)†	EULAR/ACR (2019)‡
Cardiovascular/ pulmonary	Pleuritis (pleuritic pain or rub or pleural effusion) or pericarditis (documented by electrocardiography, rub, or pericardial effusion)	Serositis (pleurisy for more than one day, pleural effusion, or pleural rub; pericardial pain for more than one day, pericardial effusion, pericardial rub, or pericarditis)	Pleural or pericardial effusion (5); acute pericarditis (6)
Constitutional	—	—	Fever > 100.9°F (38.3°C) (2)
Hematologic	Hemolytic anemia, leukopenia (< 4,000 cells per mm ³), lymphopenia (< 1,500 cells per mm ³), or thrombocytopenia (< 100,000 cells per mm ³)	Hemolytic anemia; leukopenia (< 4,000 cells per mm ³) more than once or lymphopenia (< 1,000 cells per mm ³) more than once; thrombocytopenia (< 100,000 cells per mm ³)	Leukopenia (3); thrombocytopenia (4); autoimmune hemolysis (4)
Immunologic	Positive test result for antinuclear antibodies; elevated anti-dsDNA, anti-Smith, or antiphospholipid antibodies; discoid rash; photosensitivity; oral or nasal ulcers	Positive test result for antinuclear antibodies; elevated anti-dsDNA, anti-Smith, or antiphospholipid antibodies; low complement (C3, C4, or CH 50) or direct Coombs test (in the absence of hemolytic anemia); chronic cutaneous lupus, nonscarring alopecia, or oral or nasal ulcers	Anticardiolipin immunoglobulin G or anti-beta ₂ -glycoprotein 1 antibodies or lupus anticoagulant (2); low C3 or C4 (3); low C3 and low C4 (4); anti-dsDNA or anti-Smith antibodies (6)
Integumentary/ mucosal	Malar rash	Acute cutaneous lupus or subacute cutaneous lupus	Nonscarring alopecia (2); oral ulcers (2); subacute cutaneous or discoid lupus (4); acute cutaneous lupus (6)
Musculoskeletal	Nonerosive arthritis involving two or more joints	Synovitis involving two or more joints or tenderness at two or more joints and at least 30 minutes of stiffness in the morning	Joint involvement (6)
Neuropsychiatric	Seizure or psychosis	Seizure, psychosis, mononeuritis complex, myelitis, or peripheral or cranial neuropathy	Delirium (2); psychosis (3); seizure (5)
Renal	Persistent proteinuria (> 0.5 g in 24 hours or > 3+ on urine dipstick testing) or cellular casts	Urinary creatinine (or 24-hour urinary protein) > 500 mg or red blood cell casts	Proteinuria > 0.5 g in 24 hours (4); renal biopsy class II or V lupus nephritis (8); renal biopsy class III or IV lupus nephritis (10)

ACR = American College of Rheumatology; anti-dsDNA = anti-double-stranded DNA; EULAR = European League Against Rheumatism; SLICC = Systemic Lupus International Collaborating Clinics.

*—ACR criteria have a sensitivity of 82.8% and a specificity of 93.4%; at least four of 11 criteria required for classification.

†—SLICC criteria have a sensitivity of 96.7% and a specificity of 83.7%; at least four of 13 criteria, including at least one clinical criterion and one immunologic criterion, are required for classification, or the patient must have had lupus nephritis confirmed by biopsy with a positive antinuclear or anti-dsDNA antibodies test result.

‡—EULAR/ACR criteria have a sensitivity of 96.1% and a specificity of 93.4%; a weighted score of 10 or more criteria is required for classification. The numbers in parentheses are the weighted score and should be added together to reach a total score.

Information from references 3, 7, and 8.

FIGURE 1

Patient has symptoms from multiple organ systems: cardiovascular, constitutional, gastrointestinal, hematologic, integumentary, musculoskeletal, neuropsychiatric, pulmonary, renal, reproductive, reticuloendothelial (Table 1)

Suspect SLE

Obtain antinuclear antibody titer

Negative: very low probability of SLE

Positive (i.e., antinuclear antibody titer of 1:80 or more): complete blood count with differential, urinalysis, anti-dsDNA, anti-Smith, and anticardiolipin antibodies

Meets a weighted score of 10 or more in the following 2019 European League Against Rheumatism/American College of Rheumatology criteria:

Clinical:

Acute cutaneous lupus (6); acute pericarditis (6); autoimmune hemolysis (4); delirium (2); fever (2); joint involvement (6); leukopenia (3); nonscarring alopecia (2); oral ulcers (2); pleural/pericardial effusion (5); proteinuria > 0.5 g in 24 hours (4); psychosis (3); renal biopsy class II or V lupus nephritis (8); renal biopsy class III or IV lupus nephritis (10); seizure (5); subacute cutaneous or discoid lupus (4); thrombocytopenia (4)

Immunologic:

Anticardiolipin immunoglobulin G antibodies or anti-beta₂-glycoprotein 1 antibodies or lupus anticoagulant (2); low C3 or low C4 levels (3); low C3 and low C4 levels (4); anti-dsDNA or anti-Smith antibodies (6)

SLE unlikely if no organ involvement or typical laboratory findings

Diagnose SLE

Anti-dsDNA = anti-double-stranded DNA; SLE = systemic lupus erythematosus.

Algorithm for the diagnosis of SLE in the primary care setting.

Adapted with permission from Lam NCV, Ghetu MV, Bieniek ML. Systemic lupus erythematosus: primary care approach to diagnosis and management. *Am Fam Physician.* 2016;94(4):287, with additional information from reference 7.

These weighted criteria are clinical (e.g., constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal) and immunologic (i.e., antiphospholipid antibodies, complement proteins, and SLE-specific antibodies).⁷ A diagnosis of SLE is made in consultation with a rheumatologist. *Table 1* summarizes the classification criteria of SLE.^{3,7,8}

Figure 1 presents an algorithm for the diagnosis of SLE in the primary care setting.^{7,9}

Diagnosis

CLINICAL PRESENTATION

Patients with SLE commonly present to their family physicians with multiple nonspecific symptoms, making it difficult to diagnose. Laboratory testing may be negative early in the onset of SLE. Fatigue is the most prevalent symptom and is nonspecific but may be associated with weight loss, fever without a source of infection, and joint pain.¹⁰ Malar rash (31%; *Figure 2*), photosensitivity with associated acute and subacute cutaneous lupus rash (23%; *Figure 3*⁹), pleuritic chest pain (16%), Raynaud phenomenon (16%), and mouth sores (12.5%) are less common.¹¹ The differential diagnosis for SLE is summarized in *Table 2*.¹²

INITIAL EVALUATION

SLE should be considered in patients who present with symptoms involving multiple organ systems after ruling out infectious causes. In addition to constitutional symptoms, the cardiovascular, gastrointestinal, hematologic, integumentary, musculoskeletal, neuropsychiatric, pulmonary, renal, and reproductive systems are most often affected.⁸ The reticuloendothelial system involving the phagocytic function of macrophages and monocytes also may be affected.

When SLE is clinically suspected, the diagnostic workup should collect information that allows appropriate use of new classification criteria. The EULAR/ACR classification system helps classify SLE based on a combination of physical findings and laboratory criteria. The clinician should obtain an initial ANA titer. ANA is not specific but highly sensitive in about 95% of patients.¹³ SLE is uncommon in patients with a negative ANA titer. A positive ANA titer may occur in conditions such as systemic sclerosis, diabetes mellitus, viral infections, and autoimmune thyroid disease.^{14,15}

The EULAR/ACR criteria have a sensitivity of 96% and an increased specificity of 93%. In these criteria, points are given for each clinical and immunologic criterion met. If the ANA titer is positive, the criteria are additively weighted from 2 to 10, with a score of 10 required for classification.

sific but highly sensitive in about 95% of patients.¹³ SLE is uncommon in patients with a negative ANA titer. A positive ANA titer may occur in conditions such as systemic sclerosis, diabetes mellitus, viral infections, and autoimmune thyroid disease.^{14,15}

FIGURE 2



Malar rash.


In patients with a positive ANA titer, specific laboratory tests should include anti-dsDNA, anti-Smith, anti-ribonucleoprotein, anticardiolipin, anti-beta₂-glycoprotein 1, and lupus anticoagulants, all of which can be applied to the classification system.¹² Urinalysis, comprehensive metabolic panel, complete blood count, and a direct Coombs test should be obtained with the initial evaluation. Erythrocyte sedimentation rate and C-reactive protein levels are useful in quantifying the disease activity.¹⁶

Depending on the results of the initial evaluation, further testing may include skin, kidney, muscle, or nerve biopsy. A kidney biopsy is recommended by the ACR for patients with evidence of active lupus nephritis, helping to classify the disease.¹⁷ Use of magnetic resonance imaging, computed tomography, ultrasonography, or other testing may be indicated. These results help identify existing conditions that may lead to disease flare-ups and complications and influence the treatment plan. For example, individuals with a history of seizures would require magnetic resonance imaging of the brain and electroencephalography for further workup, or patients with cognitive impairment would have a neuropsychological evaluation by a psychologist to establish a baseline.¹⁸

Assessment of Severity

A disease flare-up consists of a measurable increase in disease activity, usually leading to a change in treatment.¹⁹ Some

FIGURE 3



Subacute cutaneous lupus rash on the (A) neck and (B) back.

Reprinted with permission from Lam NCV, Ghetu MV, Bieniek ML. Systemic lupus erythematosus: primary care approach to diagnosis and management. *Am Fam Physician*. 2016;94(4):289.

TABLE 2

Differential Diagnosis of Systemic Lupus Erythematosus

Differential diagnosis	Distinguishing features	Diagnostic approach
Adult-onset Still disease	Arthralgia, fever, lymphadenopathy, splenomegaly	Elevated erythrocyte sedimentation rate, elevated ferritin level, leukocytosis, and anemia
Behçet syndrome	Aphthous ulcers, arthralgia, uveitis	Recurrent oral ulcers plus two of the following: eye lesions, genital ulcers, skin lesions
Chronic fatigue syndrome	Persistent and unexplained fatigue that significantly impairs daily activities	Perform the following tests to rule out other diseases: complete blood count, erythrocyte sedimentation rate, C-reactive protein level, complete metabolic panel, thyroid-stimulating hormone, urinalysis
Endocarditis	Arterial emboli, arthralgia, fever, heart murmur, myalgia	Positive echocardiography findings with vegetation on heart valve; positive blood culture
Fibromyalgia	Poorly localized musculoskeletal pain with hyperalgesia and allodynia	Digital palpation of soft tissue tender points: gluteal, greater trochanter, knee, lateral epicondyle, low cervical, occiput, second rib, supraspinatus, trapezius
HIV infection	Arthralgia, fever, lymphadenopathy, malaise, myalgia, peripheral neuropathy, rash	Western blot assay for detection of HIV antibodies
Inflammatory bowel disease	Diarrhea, peripheral arthritis, rectal bleeding, tenesmus	Perform colonoscopy to assess disease activity; measure C-reactive protein level, platelets, and erythrocyte sedimentation rate; test for anemia
Lyme disease	Arthritis, carditis, erythema migrans, neuritis	Perform serologic testing for Lyme disease
Mixed connective tissue disease	Arthralgia, myalgia, puffy fingers, Raynaud phenomenon, sclerodactyly	Elevated erythrocyte sedimentation rate and hypergammaglobulinemia; positive anti-U1RNP antibodies
Psoriatic arthritis	Psoriasis before or after joint disease, nail changes in fingers and toes	Inflammatory articular disease and more than three of the following: dactylitis, nail changes, negative rheumatoid factor, psoriasis, radiographic evidence of new bone formation in hand or foot
Reactive arthritis	Acute nonpurulent arthritis from infection elsewhere in the body; evaluate for infectious urethritis or colitis	Clinical diagnosis to identify triggers; serologic findings of recent infections may be present
Rheumatoid arthritis	Morning joint stiffness lasting more than one hour; affected joints are usually symmetrical, tender, and swollen	Positive test results for rheumatoid factor and anti-cyclic citrullinated antibodies; synovial fluid reflects inflammatory state
Sarcoidosis	Cough, dyspnea, fatigue, fever, night sweats, rash, uveitis	Perform chest radiography; bilateral adenopathy with biopsy revealing noncaseating granuloma; elevated angiotensin-converting enzyme level
Systemic sclerosis	Arthralgia, decreased joint mobility, myalgia, Raynaud phenomenon, skin induration	Perform tests for specific autoantibodies
Thyroid disease	Dry skin, fatigue, feeling cold, weakness	Measure thyroid-stimulating hormone

Information from reference 12.

circumstances that increase disease flare-ups include sunlight exposure, hormonal changes, infection, and medications.

There are multiple tools to assess disease severity, but the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) is the most commonly used. The tool is available online at <https://www.mdcalc.com/calc/10099/systemic-lupus-erythematosus-disease-activity-index-2000-sledai-2k>.

A disease flare-up is classified as mild, moderate, or severe depending on the disease activity.^{20,21} Mild disease has a

SLEDAI-2K score of 6 or less, moderate disease has a score of 7 to 12, and severe disease has a score of more than 12.¹⁹

Management

GOALS OF TREATMENT

Management of SLE is directed at achieving complete remission or low disease activity, minimizing the use of glucocorticoids, preventing flare-ups, and improving quality of life.^{19,22,23} Complete remission is defined as the absence of clinical activity (i.e., a SLEDAI-2K score of 0) with no use

of glucocorticoid or immunosuppressive therapy.²⁴ Low disease activity is a SLEDAI-2K score of 3 or less while on anti-malarials (e.g., hydroxychloroquine), or a SLEDAI-2K score of 4 or less while taking no more than 7.5 mg per day of prednisone and well-tolerated immunosuppressive agents.²⁵ Therapies are typically managed by or co-managed with experts in rheumatology. Management in severe disease may require a multidisciplinary approach.¹⁹ Table 3 lists medications used to treat SLE.^{8,17,26-28}

PHARMACOTHERAPY

Hydroxychloroquine. Hydroxychloroquine is recommended for all patients with SLE because it prevents flare-ups, organ damage, and thrombosis and increases long-term survival.^{19,29} It has a long half-life and may take two to eight weeks to be effective. Retinal toxicity is the main adverse effect. Based on existing evidence that shows the risk of toxicity is very low for doses below 5 mg per kg of body weight, the daily dosage should not exceed this threshold.¹⁹ Risk factors for retinal toxicity include longer duration of use, higher dosage, preexisting retinal or macular disease, older age, concomitant use of tamoxifen, and kidney and liver disease.^{19,30} Baseline fundoscopic examination, visual field testing, and spectral-domain optical coherence tomography should be performed to rule out preexisting maculopathy at the time of initiation. Annual screening should be performed in those at high risk but can be deferred to five years in low-risk patients.^{29,31}

Glucocorticoids. Glucocorticoids provide rapid symptom relief in acute disease and during flare-ups. Prolonged glucocorticoid use can have detrimental effects, including irreversible organ damage. The aim should be to minimize the daily dosage of prednisone to 7.5 mg or less or discontinue glucocorticoids.³² Early initiation of immunosuppressive agents helps

patients to taper and eventually discontinue glucocorticoids. High-dose intravenous methylprednisolone (usually

TABLE 3

Medications Used to Treat Systemic Lupus Erythematosus

Medication	Indication	Dosage
First-line treatment		
Glucocorticoids	Low dose for treating SLE without major organ damage; high dose for cerebritis, lupus nephritis, refractory conditions, and thrombocytopenia	Low dose: ≤ 7.5 mg of prednisone per day High dose: 40 to 60 mg of prednisone per day
Hydroxychloroquine	Recommended for all patients with SLE; long-term protective effect on SLE-related organ damage	5 mg per kg of body weight per day (200 to 400 mg per day)
Nonsteroidal anti-inflammatory drugs	Lupus joint pain	Depends on preparation
Second-line treatment		
Azathioprine	Lupus nephritis, severe SLE	1.5 to 2.5 mg per kg per day
Methotrexate	Arthritis, cutaneous lupus, serositis, severe SLE	7.5 to 25 mg per week
Third-line treatment		
Anifrolumab (Saphnelo)	Moderate and severe SLE, lupus nephritis	300 mg every four weeks administered via intravenous infusion
Belimumab (Benlysta)	SLE	10 mg per kg per intravenous dose 200 mg subcutaneously once per week
Cyclophosphamide	Lupus nephritis, severe SLE	500 to 1,000 mg per m ² intravenously once per month
Mycophenolate mofetil	Lupus nephritis, refractory SLE	2 to 3 g per day
Rituximab (Rituxan)	Refractory severe SLE	One-time administration of two 1-g doses intravenously, two weeks apart
Voclosporin (Lupkynis)	Lupus nephritis	23.7 mg orally every 12 hours

SLE = systemic lupus erythematosus.

*—Estimated lowest GoodRx price for one month’s treatment unless otherwise noted. Actual cost will vary with insurance and by region. Generic price listed first; brand name price in parentheses. Information obtained at <https://www.goodrx.com> (accessed January 26, 2023; zip code: 66211).

Information from references 8, 17, and 26-28.

SYSTEMIC LUPUS ERYTHEMATOSUS

250 to 1,000 mg per day for three days) may be used in acute, organ-threatening disease or during severe flare-ups.³³

Immunosuppressive Therapy. The choice of agent depends on disease manifestations, patient age, childbearing potential, safety concerns, and cost.¹⁹ Methotrexate and azathioprine may be considered if a trial of hydroxychloroquine fails to manage the disease or glucocorticoids cannot be tapered off. Mycophenolate mofetil is a potent immunosuppressant with effectiveness in renal and nonrenal lupus.^{34,35} Cyclophosphamide may be used in organ-threatening disease, especially affecting the renal, cardiopulmonary, or neuropsychiatric systems.

Biologic Agents. Belimumab (Benlysta), a B lymphocyte stimulating factor, is used in SLE and lupus nephritis when first-line treatments provide inadequate control. Patients more likely to respond are those with high disease activity, who are taking a prednisone dosage of more than 7.5 mg per day, and with serologic activity (low C3/C4, high anti-dsDNA antibody titers).^{36,37}

Several open-label trials and registry studies have found that rituximab (Rituxan) is effective in SLE that is resistant to standard treatment. Because of insufficient evidence from randomized controlled trials, rituximab is currently used off-label in patients with severe renal, hematologic, and neuropsychiatric disease; in patients with SLE that has been resistant to other immunosuppressive agents and/or belimumab; or in patients for whom other therapeutic options are contraindicated. More than one immunosuppressive drug needs to have been ineffective before administering rituximab.^{38,39}

Voclosporin (Lupkynis) is an oral calcineurin inhibitor immunosuppressant approved by the U.S. Food and Drug Administration in 2021 for the treatment of lupus nephritis in combination with mycophenolate mofetil and glucocorticoids.²⁷ Anifrolumab (Saphnelo) is an immunoglobulin gamma 1 kappa monoclonal

Monitoring and precautions	Cost*
Glucose levels every three to six months and total cholesterol and bone density testing annually; use with caution in patients with hyperlipidemia, hypertension, hyperglycemia, infection, or osteoporosis	\$5 (—) for 30 10-mg prednisone tablets; \$7 (—) for 60 20-mg prednisone tablets
Baseline funduscopic examination, visual field testing, and spectral-domain optical coherence tomography should be performed at the time of initiation; annual screening is performed in those at high risk but can be deferred to every five years in low-risk patients at the time of initiation, then annually	\$6 (—) for 30 200-mg tablets
Complete blood count and renal testing annually; use with caution in patients with gastrointestinal bleeding, liver or kidney disease, or hypertension	Depends on preparation
Complete blood count and metabolic panel at least every three months to monitor for hepatotoxicity, lymphoproliferative disorders, and myelosuppression	\$15 (—) for 60 50-mg tablets
Complete blood count and metabolic panel at least every three months to monitor for hepatic fibrosis or myelosuppression; additional monitoring for fibrosis and pulmonary infiltrates	\$3 (—) for 12 2.5-mg tablets
Monitor for respiratory tract infections and hypersensitivity	Only administered by a health care professional
Monitor for serious infection and malignancies	Only available at specialty pharmacies
Complete blood count and metabolic panel at least every three months to monitor for hemorrhagic cystitis, immunosuppression, malignancy, and myelosuppression	Only administered by a health care professional
Complete blood count and metabolic panel at least every three months to monitor for infection and myelosuppression	\$30 (—) for 240 250-mg capsules
Complete blood count every two to four months; use with caution in patients with a history of infusion reaction	Only available at specialty pharmacies
Establish baseline estimated glomerular filtration rate prior to initiating, then every two weeks for the first month and every four weeks thereafter; monitor blood pressure every two weeks	Only available at specialty pharmacies

SYSTEMIC LUPUS ERYTHEMATOSUS

antibody antagonist of the type 1 interferon receptor and was approved by the U.S. Food and Drug Administration in 2021 for the treatment of moderate and severe SLE.²⁸

SPECIFIC ORGAN SYSTEM COMPLICATIONS

Screening for nephritis with urinalysis and serum creatinine levels should be done at three- to six-month intervals in all patients with SLE. For patients with features suggesting nephritis, a 24-hour urine test for protein or a spot urine protein/creatinine ratio should be obtained.¹⁷ Referral for renal biopsy should be considered in patients with proteinuria of at least 1 g in 24 hours or at least 0.5 g in 24 hours with hematuria or cellular casts. Mycophenolate

mofetil and cyclophosphamide are the immunosuppressive agents of choice for induction therapy for lupus nephritis. Mycophenolate mofetil or azathioprine may be used for maintenance therapy. Management of specific organ systems in patients with SLE is summarized in *Table 4*.^{19,40-45} *Figure 4* outlines the management of nonrenal SLE.^{19,46}

PREGNANCY COMPLICATIONS

Pregnant patients with SLE have an increased risk of spontaneous abortions, stillbirths, fetal growth restriction, and preeclampsia.²⁶ Pregnancy may increase disease activity and precipitate disease flare-ups.⁴⁷


TABLE 4

Management of Specific Systemic Manifestations of Systemic Lupus Erythematosus

Organ system	Lifetime prevalence	Treatment	Prevention and screening
Cardiovascular	28% to 40%	Antihypertensive agents, cholesterol-lowering agents	Treat risk factors aggressively
Hematologic	Most patients	Thrombocytopenia: First line: glucocorticoids plus immunosuppressive therapy (i.e., azathioprine, mycophenolate mofetil, or cyclosporine); intravenous methylprednisolone with or without intravenous immunoglobulins Refractory: rituximab Autoimmune hemolytic anemia: glucocorticoids plus immunosuppressive therapy	Monitor and treat infection, especially in patients with leukopenia
Integumentary	70% to 80%	First line: topical agents (e.g., glucocorticoids, calcineurin inhibitors) and hydroxychloroquine with or without systemic glucocorticoids. Refractory: methotrexate; other agents include retinoids, dapsone (Aczone), and mycophenolate mofetil	Use sunscreen and wear protective clothing
Musculoskeletal	95%	First line: nonsteroidal anti-inflammatory drugs, hydroxychloroquine, glucocorticoids Refractory: immunosuppressive therapy such as methotrexate or mycophenolate mofetil	—
Neuropsychiatric	12% to 23%	Based on etiology: Inflammatory: glucocorticoids with or without immunosuppressive therapy Embolic/thrombotic/ischemic: anticoagulant	Control aggravating factors and symptoms
Pulmonary	16%	Depends on type of involvement and severity; glucocorticoids, azathioprine, cyclophosphamide, or mycophenolate mofetil; plasmapheresis	—
Renal	50%	Induction: mycophenolate mofetil or cyclophosphamide Maintenance: mycophenolate mofetil or azathioprine	Urinalysis and serum creatinine test every one to three months

Information from references 19 and 40-45.

FIGURE 4



SLE = systemic lupus erythematosus; SLEDAI-2K = Systemic Lupus Erythematosus Disease Activity Index 2000.

Algorithm for the management of nonrenal SLE.

Information from references 19 and 46.

Active disease six months before pregnancy, lupus nephritis, and discontinuation of antimalarial agents are risk factors for adverse maternal outcomes.²⁹ Preconception counseling regarding risks, planning the timing of pregnancy, and using a multidisciplinary approach play a major role in the management of SLE in patients contemplating pregnancy.

Hydroxychloroquine should be continued during pregnancy because it has been shown to control disease activity. It may reduce pregnancy complications, including preeclampsia and cardiac neonatal lupus.⁴⁷⁻⁵⁰ Prednisone, azathioprine, and tacrolimus may be used in pregnancy if benefits outweigh risks, whereas methotrexate, mycophenolate mofetil, cyclophosphamide, and leflunomide are contraindicated in pregnancy. Mycophenolate mofetil is highly teratogenic and should be discontinued at least six weeks before conceiving. These patients can be switched to azathioprine and/or tacrolimus at least three months before conception to help decrease disease activity. According to the U.S. Preventive Services Task Force, low-dose aspirin should be initiated in pregnant patients with an increased risk of preeclampsia after 12 weeks of gestation.⁵¹

Patients should be closely monitored throughout pregnancy to detect and manage complications or flare-ups. Patients with SLE and antiphospholipid syndrome may need additional anticoagulant agents throughout pregnancy and in the postpartum period.

Other than a consultation with a physician specializing in maternal-fetal medicine and a rheumatologist, the evaluation should include an assessment of antiphospholipid antibodies and anti-Ro/SS-A and anti-La/SS-B antibodies. Anti-Ro and anti-La antibodies may be present in patients with SLE and can be cardiotoxic to the fetus. Varying degrees of congenital heart block can be seen in 1% to 3% of children born to patients who are seropositive.⁵² Heart block can be incomplete or complete, leading to heart failure in utero and hydrops fetalis. For patients with anti-Ro and anti-La antibodies, fetal echocardiography should be performed multiple times from 16 through 26 weeks of gestation; this period is when the fetus has the highest risk for onset of congenital heart block.²⁹ There is no known effective therapy for complete heart block, but incomplete heart block is often treated with dexamethasone because it can cross the placenta. Hydroxychloroquine use during

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
Treatment of systemic lupus erythematosus should aim for complete remission or low disease activity and prevention of flare-ups in all organs using the lowest possible dose of glucocorticoids. ^{19,22,23}	C	Expert opinion and consensus guideline
Hydroxychloroquine is recommended for all patients with systemic lupus erythematosus. ^{19,29}	C	Consensus guideline based on inconsistent or limited-quality patient-oriented evidence
Hydroxychloroquine should be continued during pregnancy because it has been shown to control disease activity. It may reduce pregnancy complications, including preeclampsia and cardiac neonatal lupus. ⁴⁷⁻⁵⁰	B	Inconsistent or limited-quality patient-oriented evidence and expert opinion
Patients with active disease should be evaluated at least every one to three months, and measurements of blood pressure, anti-double-stranded DNA antibodies, and complement and C-reactive protein levels; urinalysis; complete blood count; and kidney and liver function tests should be performed. ⁴⁶	C	Expert opinion and consensus guideline

A = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to <https://www.aafp.org/afpsort>.

pregnancy is associated with a reduced risk of fetal development of cardiac neonatal lupus.⁴⁹

CONTRACEPTION

Patients with SLE can use most contraceptive methods, preferably long-acting reversible contraception such as intrauterine devices. Those with antiphospholipid syndrome should not use estrogen-containing contraceptives because of increased risk of thrombosis.⁵³

Monitoring

SLE has wide-ranging effects on physical, psychological, and social well-being that impact quality of life. All patients with SLE should receive ongoing education, counseling, and support. Those with mild SLE can be monitored by primary care physicians in conjunction with rheumatology.⁸ Patients with increased disease activity, complications, or adverse effects from treatment should be managed by a rheumatologist.⁸ Family physicians can assist the rheumatologist in monitoring disease activity and providing pharmacotherapy in patients with moderate to severe SLE. Those with active disease should be evaluated at least every one to three months, and measurements of blood pressure, anti-dsDNA antibodies, complement and C-reactive protein levels; urinalysis; complete blood count; and kidney and liver function tests should be performed. Patients with stable low disease activity or who are in remission can be evaluated less often.⁴⁶

Patients with chronic kidney disease should receive one dose of pneumococcal conjugate vaccine (PCV20 or PCV15). When PCV15 is used, it should be followed by a dose of pneumococcal polysaccharide vaccine (PPSV23).⁵⁴ Live vaccines should not be given to patients with SLE when they are receiving immunosuppressive therapy and should be delayed for at least one month after completion of therapy.

Management of modifiable risk factors, including hypertension, dyslipidemia, diabetes, high body mass index, and smoking, should be reviewed at baseline and at least annually. Immunosuppressive therapy may lead to toxicities. Close monitoring of medications by regular laboratory testing and clinical assessment should be performed in accordance with drug monitoring guidelines.⁴⁶

Table 5 describes recommendations for follow-up and monitoring for complications related to SLE.^{8,17,46,55-57}

This article updates previous articles on this topic by Lam, et al.⁹; Gill, et al.⁵⁸; and Petri.⁵⁹

Data Sources: Dynamed, PubMed, Cochrane Database of Systematic Reviews, Essential Evidence Plus, including POEMs, the U.S. Preventive Services Task Force, and the Centers for Disease Control and Prevention vaccine guidelines were searched using key words systemic lupus erythematosus, lupus nephritis, SLE diagnosis, and SLICC. The American College of Rheumatology, the British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults, and the American College of Obstetricians and Gynecologists practice guidelines were also searched. We used references from the previous AFP articles on this topic. Search dates: April and May 2022, and January 2023.

TABLE 5

Follow-up, Monitoring, and Management for Selected Complications of Systemic Lupus Erythematosus

Complications	Frequency of follow-up	Prevention, monitoring, and management
None; mild, stable systemic lupus erythematosus	Every three to six months	History for features of systemic lupus erythematosus, physical examination, complete blood count, creatinine level, urinalysis, anti-double-stranded DNA antibodies, complement levels; keep all health maintenance screenings and vaccinations up to date
Moderate to severe systemic lupus erythematosus with complications	Frequent	Monitor as recommended by rheumatologist and lupus care specialists
Systems monitoring		
Cardiovascular abnormalities	Every visit	Optimal lupus control with minimal glucocorticoid use; judicious use of antimalarial and other immunosuppressive agents; smoking cessation, adequate exercise, low-cholesterol diet, lipid-lowering therapy, blood pressure control, screening for diabetes mellitus
Hematology: severe hemolytic anemia	Weekly	Hematocrit and reticulocyte count; may require transfusion
Hematology: severe thrombocytopenia (< 50,000 cells per mm ³)	Weekly	Platelet count weekly initially; may require transfusion
Infection	Every visit	Ensure that vaccinations are up to date; judicious use of immunosuppressive agents
Malignancy	Yearly	Ensure that routine cancer screenings are up to date; screen for high-risk cancers as indicated (e.g., hematologic, non-Hodgkin lymphoma, lung, cervical)
Renal abnormalities	Every three months or more frequently, depending on disease state	Regular screening for proteinuria and hematuria; regular serum creatinine level; patients with chronic kidney disease should receive pneumococcal vaccination; new-onset nephritis needs more frequent monitoring
Medication monitoring		
Hydroxychloroquine	Annual vision screening is performed in those at high risk but can be deferred to five years in low-risk patients at the time of initiation, then annually	Baseline funduscopic examination, visual field testing, and spectral-domain optical coherence tomography should be performed at the time of initiation
Low-dose glucocorticoids	Every visit to every one to two years	Keep dosage as low as possible; healthy diet with adequate physical activity; smoking cessation; annual cholesterol and glucose testing; consider dual-energy x-ray absorptiometry every one to two years for patients receiving long-term therapy
High-dose glucocorticoids (e.g., prednisone, > 30 mg per day)	Every visit	Pursue steroid-sparing agent; use lowest dose possible to achieve optimum disease control; glucose testing every three to six months; cholesterol testing annually; dual-energy x-ray absorptiometry every one to two years; maintain high index of suspicion for avascular necrosis if patient has acute joint pain
Immunosuppressive or cytotoxic agents	Every one to two weeks initially, then every one to three months	Complete blood count and liver function testing at baseline, then every one to two weeks at initiation of therapy, then one to three months; judicious use of immunosuppressive agents, vigilance for signs and symptoms of infection; routine cancer screening; avoidance of live vaccines; if live vaccines are needed, administer one month after completion of therapy

Information from references 8, 17, 46, and 55-57.

The Authors

NGUYET-CAM V. LAM, MD, FAAFP, is the program director of St. Luke's Bethlehem (Pa.) Family Medicine Residency at St. Luke's University Hospital.

JUDY ABU BROWN, MD, is a clinical faculty member at St. Luke's Bethlehem Family Medicine Residency at St. Luke's University Hospital.

RICHA SHARMA, MD, is a clinical faculty member at St. Luke's Bethlehem Family Medicine Residency at St. Luke's University Hospital.

Address correspondence to *Nguyet-Cam V. Lam, MD, FAAFP, St. Luke's Hospital, 2830 Easton Ave., Bethlehem, PA 18017 (email: nguyet-cam.lam@sluhn.org). Reprints are not available from the authors.*

References

1. Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. *Rheumatology (Oxford)*. 2017;56(11):1945-1961.
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. 1982;25(11):1271-1277.
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum*. 1997;40(9):1725.
4. Lim SS, Bayakly AR, Helmick CG, et al. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the Georgia Lupus Registry. *Arthritis Rheumatol*. 2014;66(2):357-368.
5. Somers EC, Marder W, Cagnoli P, et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. *Arthritis Rheumatol*. 2014;66(2):369-378.
6. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum*. 2012;64(8):2677-2686.
7. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Arthritis Rheumatol*. 2019;71(9):1400-1412.
8. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. *Arthritis Rheum*. 1999;42(9):1785-1796.
9. Lam NCV, Ghetu MV, Bieniek ML. Systemic lupus erythematosus: primary care approach to diagnosis and management. *Am Fam Physician*. 2016;94(4):284-294.
10. Zonana-Nacach A, Roseman JM, McGwin G Jr., et al. Systemic lupus erythematosus in three ethnic groups. VI: factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. Lupus in minority populations: nature vs nurture. *Lupus*. 2000;9(2):101-109.
11. Cervera R, Khamashta MA, Font J, et al.; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine (Baltimore)*. 2003;82(5):299-308.
12. Longo DL, Fauci AS, Kasper DL, et al., eds. *Harrison's Principles of Internal Medicine*. 18th ed. McGraw-Hill; 2012.
13. Hietarinta M, Lassila O. Clinical significance of antinuclear antibodies in systemic rheumatic diseases. *Ann Med*. 1996;28(4):283-291.
14. Sherer Y, Gorstein A, Fritzler MJ, et al. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. *Semin Arthritis Rheum*. 2004;34(2):501-537.
15. Goldblatt F, O'Neill SG. Clinical aspects of autoimmune rheumatic diseases. *Lancet*. 2013;382(9894):797-808.
16. Narain S, Richards HB, Satoh M, et al. Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting. *Arch Intern Med*. 2004;164(22):2435-2441.
17. Hahn BH, McMahon MA, Wilkinson A, et al.; American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis Care Res (Hoboken)*. 2012;64(6):797-808.
18. Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. *Ann Rheum Dis*. 2010;69(12):2074-2082.
19. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78(6):736-745.
20. Lisnevskaja L, Murphy G, Isenberg D. Systemic lupus erythematosus. *Lancet*. 2014;384(9957):1878-1888.
21. Ruperto N, Hanrahan LM, Alarcón GS, et al.; Lupus Foundation of America, Inc.; International Flare Consensus Initiative. International consensus for a definition of disease flare in lupus. *Lupus*. 2011;20(5):453-462.
22. van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Ann Rheum Dis*. 2017;76(3):554-561.
23. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. *Ann Rheum Dis*. 2014;73(6):958-967.
24. Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, et al.; GLADEL. Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). *Ann Rheum Dis*. 2017;76(12):2071-2074.
25. Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, et al. Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. *Rheumatology (Oxford)*. 2017;56(1):121-128.
26. Muangchan C, van Vollenhoven RF, Bernatsky SR, et al. Treatment algorithms in systemic lupus erythematosus. *Arthritis Care Res (Hoboken)*. 2015;67(9):1237-1245.
27. Heo YA. Voclosporin: first approval. *Drugs*. 2021;81(5):605-610.
28. Deeks ED. Anifrolumab: first approval. *Drugs*. 2021;81(15):1795-1802.
29. Chowdhary VR. Broad concepts in management of systemic lupus erythematosus. *Mayo Clin Proc*. 2017;92(5):744-761.
30. Kim JW, Kim YY, Lee H, et al. Risk of retinal toxicity in longterm users of hydroxychloroquine. *J Rheumatol*. 2017;44(11):1674-1679.
31. Marmor MF, Kellner U, Lai TYY, et al.; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). *Ophthalmology*. 2016;123(6):1386-1394.
32. Chen HL, Shen LJ, Hsu PN, et al. Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. *J Rheumatol*. 2018;45(1):83-89.
33. Singh JA, Hossain A, Kotb A, et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. *BMC Med*. 2016;14(1):137.
34. Tselios K, Gladman DD, Su J, et al. Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. *J Rheumatol*. 2016;43(3):552-558.

SYSTEMIC LUPUS ERYTHEMATOSUS

35. Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and meta-analysis. *J Rheumatol*. 2011;38(1):69-78.
36. Iaccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. *J Autoimmun*. 2018;86:1-8.
37. Manzi S, Sánchez-Guerrero J, Merrill JT, et al.; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. *Ann Rheum Dis*. 2012;71(11):1833-1838.
38. Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. *Lupus*. 2013;22(14):1489-1503.
39. Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. *Lupus*. 2009;18(9):767-776.
40. Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. *Lupus*. 2014;23(3):225-235.
41. Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. *J Am Acad Dermatol*. 2011;65(4):717-721.e2.
42. Kuhn A, Aberer E, Bata-Csörgő Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). *J Eur Acad Dermatol Venereol*. 2017;31(3):389-404.
43. Roenigk HH Jr., Martin JS, Eichorn P, et al. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. *Cutis*. 1980;25(3):281-285.
44. Olfat M, Silverman ED, Levy DM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. *Lupus*. 2015;24(9):966-972.
45. Dooley MA, Jayne D, Ginzler EM, et al.; ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. *N Engl J Med*. 2011;365(20):1886-1895.
46. Gordon C, Amisssah-Arthur MB, Gayed M, et al.; British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. *Rheumatology (Oxford)*. 2018;57(1):e1-e45.
47. Bertias G, Fanouriakis A, Boumpas DT. Treatment of systemic lupus erythematosus. In: Kelley WN, Firestein GS, eds. *Kelley's Textbook of Rheumatology*. 9th ed. Saunders; 2013:1304-1330.
48. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. *Lupus*. 2001;10(6):401-404.
49. Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. *Ann Rheum Dis*. 2010;69(10):1827-1830.
50. Clowse MEB, Eudy AM, Balevic S, et al. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. *Lupus Sci Med*. 2022;9(1):e000651.
51. LeFevre ML; U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2014;161(11):819-826.
52. Brucato A, Cimaz R, Caporali R, et al. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. *Clin Rev Allergy Immunol*. 2011;40(1):27-41.
53. Culwell KR, Curtis KM, Del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. *Obstet Gynecol*. 2009;114(2 pt 1):341-353.
54. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(4):109-117.
55. Gordon C. Long-term complications of systemic lupus erythematosus. *Rheumatology (Oxford)*. 2002;41(10):1095-1100.
56. McMahon M, Hahn BH, Skaggs BJ. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. *Expert Rev Clin Immunol*. 2011;7(2):227-241.
57. Sivaraj RR, Durrani OM, Denniston AK, et al. Ocular manifestations of systemic lupus erythematosus. *Rheumatology (Oxford)*. 2007;46(12):1757-1762.
58. Gill JM, Quisel AM, Rocca PV, et al. Diagnosis of systemic lupus erythematosus. *Am Fam Physician*. 2003;68(11):2179-2186.
59. Petri M. Treatment of systemic lupus erythematosus: an update. *Am Fam Physician*. 1998;57(11):2753-2760.